PPMS PBiPS9-Sv4F-12

General

Cell Line

hPSCreg name ESi124-A
Cite as:
ESi124-A (RRID:CVCL_D6HW)
Alternative name(s)
PPMS PBiPS9-Sv4F-12
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
MNZTASi006-A
(MS_0005, TOB-02161, 2161-4)
Donor diseases:
primary progressive multiple sclerosis
ESi123-A
(PPMS PBiPS8-Sv4F-13)
Donor diseases:
primary progressive multiple sclerosis
ESi122-A
(PPMS PBiPS7-Sv4F-5)
Donor diseases:
primary progressive multiple sclerosis
ESi128-A
(PPMS PBiPS10-Sv4F-1)
Donor diseases:
primary progressive multiple sclerosis
MNZTASi001-A
(MS_0004, 2125-2, TOB-02125)
Donor diseases:
primary progressive multiple sclerosis
Last update 14th February 2024
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Spanish Stem Cell Bank (ES)
Owner Regenerative Medicine Program. Bellvitge Biomedical Research Institute
Distributors
Derivation country Spain

External Databases

BioSamples SAMEA115283713
Cellosaurus CVCL_D6HW
Wikidata Q127380834

General Information

* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex female
Age of donor (at collection) 65-69
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
HLA-DRB1*15:01 haplotype
Synonyms
  • PPMS
  • primary-progressive MS
Is the medical history available upon request? Yes, request to Dr. Manuel Comabella.
Is clinical information available? Yes, request to Dr. Manuel Comabella.

Karyotyping (Donor)

Has the donor karyotype been analysed?
Unknown

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA115283714

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Please provide the contact information Dr. Manuel Comabella, Vall d’Hebron Institut de Recerca (VHIR) - Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Yes
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Induced Pluripotent stem cell-based human glial chimeric mice to study oligodendrocyte pathology in primary progressive multiple sclerosis pantients
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? Yes
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? Yes
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? No
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Dr. Manuel Comabella, Vall d’Hebron Institut de Recerca (VHIR) - Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website: Dr. Manuel Comabella, Vall d’Hebron Institut de Recerca (VHIR) - Centre d’Esclerosi Múltiple de Catalunya (Cemcat)
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? Ethical Committee for Clinical Research in Regenerative Medicine. IDIBELL
Approval number 25/2020
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? Ethical Committee for Clinical Research in Regenerative Medicine. IDIBELL
Approval number 25/2020
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? Yes
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? Cytotune
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
  • PERIPHERAL BLOOD MONONUCLEAR CELL
  • Peripheral Blood Mononuclear Cell
  • PBMC
Source cell origin
Blood drawn from a limb.
Synonyms
  • Peripheral Blood
  • Peripheral blood
Age of donor (at collection) 65-69
Collected in 2022
Passage number reprogrammed 1

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Genes
Is reprogramming vector detectable?
No
Methods used
PCR
Files and images showing reprogramming vector expressed or silenced

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Good morphology, absent of spontaneous differentiation, correct karyotype and abscence of the reprogramming factors.
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Supplements
P/S 0.5 %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
Alkaline Phosphatase
Yes
NANOG
Yes
POU5F1 (OCT-4)
Yes
SOX2
Yes
SSEA-3
Yes
SSEA-4
Yes
TRA 1-60
Yes
TRA 1-81
Yes
Differentiation Potency
Mesoderm
Ont Id: UBERON_0000926
In vitro directed differentiation
Marker Expressed
ASMA
Yes
GATA4
Yes
Ectoderm
Ont Id: UBERON_0000924
In vitro directed differentiation
Marker Expressed
Tuj1
Yes
GFAP
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XX
Passage number: 19
Karyotyping method: G-Banding

Other Genotyping (Cell Line)